Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

Lack of consensus for first‐line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first‐l...

Descripción completa

Detalles Bibliográficos
Autores principales: Becnel, Melody R., Nastoupil, Loretta J., Samaniego, Felipe, Davis, Richard E., You, M. J., Green, Michael, Hagemeister, Fredrick B., Fanale, Michelle A., Fayad, Luis E., Westin, Jason R., Wang, Michael, Oki, Yasuhiro, Forbes, Sheryl G., Feng, Lei, Neelapu, Sattva S., Fowler, Nathan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619290/
https://www.ncbi.nlm.nih.gov/pubmed/30919940
http://dx.doi.org/10.1111/bjh.15843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619290/
https://www.ncbi.nlm.nih.gov/pubmed/30919940
http://dx.doi.org/10.1111/bjh.15843

Ejemplares similares